公开(公告)号：US20250059158A1

公开(公告)日：2025-02-20

申请号：US18586019

申请日：2024-02-23

Applicant: Karyopharm Therapeutics Inc.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  Dilara McCauley ,  Trinayan Kashyap ,  William Senapedis ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shedhter

IPC: C07D401/06 ,  C07D249/08 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

公开(公告)号：US11124493B2

公开(公告)日：2021-09-21

申请号：US16519955

申请日：2019-07-23

Applicant: Karyopharm Therapeutics Inc.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  Dilara McCauley ,  Trinayan Kashyap ,  William Senapedis ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shechter

IPC: A61K31/506 ,  A61P35/00 ,  C07D403/06 ,  C07D401/06 ,  C07D249/08 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

公开(公告)号：US10407405B2

公开(公告)日：2019-09-10

申请号：US15651856

申请日：2017-07-17

Applicant: Karyopharm Therapeutics Inc.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  Dilara McCauley ,  Trinayan Kashyap ,  William Senapedis ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shechter

IPC: A61K31/4196 ,  C07D249/08 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

公开(公告)号：US09856241B2

公开(公告)日：2018-01-02

申请号：US14902202

申请日：2014-07-03

Applicant: Karyopharm Therapeutics Inc.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  William Senapedis ,  Dilara McCauley ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shechter

IPC: C07D405/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D307/81 ,  C07D413/14 ,  C07D491/048 ,  C07D491/08

CPC classification number: C07D405/14 ,  C07D307/81 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D491/048 ,  C07D491/08

Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (A), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

公开(公告)号：US20240376114A1

公开(公告)日：2024-11-14

申请号：US18526900

申请日：2023-12-01

Applicant: Karyopharm Therapeutics Inc.

Inventor： Vincent P. Sandanayaka ,  Sharon Shacham ,  Michael Kauffman ,  Sharon Shechter ,  Dilara McCauley ,  Yosef Landesman ,  William Senapedis ,  Jean-Richard Saint-Martin

IPC: C07D487/10 ,  C07D213/50 ,  C07D401/06 ,  C07D401/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

公开(公告)号：US20220177445A1

公开(公告)日：2022-06-09

申请号：US17409150

申请日：2021-08-23

Applicant: Karyopharm Therapeutics Inc.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  Dilara McCauley ,  Trinayan Kashyap ,  William Senapedis ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shechter

IPC: C07D401/06 ,  C07D249/08 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

公开(公告)号：US20210403459A1

公开(公告)日：2021-12-30

申请号：US17205797

申请日：2021-03-18

Applicant: Karyopharm Therapeutics Inc.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  William Senapedis ,  Dilara McCauley ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shechter

IPC: C07D405/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D307/81 ,  C07D413/14 ,  C07D491/048 ,  C07D491/08

Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

公开(公告)号：US20200087313A1

公开(公告)日：2020-03-19

申请号：US16394986

申请日：2019-04-25

Applicant: Karyopharm Therapeutics Inc.

Inventor： Vincent P. Sandanayaka ,  Sharon Shacham ,  Michael Kauffman ,  Sharon Shechter ,  Dilara McCauley ,  Yosef Landesman ,  William Senapedis ,  Jean-Richard Saint-Martin

IPC: C07D487/10 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D401/08 ,  C07D401/12 ,  C07D403/14 ,  C07D413/12 ,  C07D403/06 ,  C07D401/06 ,  C07D213/50

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

公开(公告)号：US20180319779A1

公开(公告)日：2018-11-08

申请号：US15831111

申请日：2017-12-04

Applicant: Karyopharm Therapeutics Inc.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  William Senapedis ,  Dilara McCauley ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shechter

IPC: C07D405/14 ,  C07D491/08 ,  C07D491/048 ,  C07D413/14 ,  C07D307/81 ,  C07D413/12 ,  C07D409/14 ,  C07D405/12 ,  C07D417/12

CPC classification number: C07D405/14 ,  C07D307/81 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D491/048 ,  C07D491/08

Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

公开(公告)号：US20160152596A1

公开(公告)日：2016-06-02

申请号：US14900469

申请日：2014-06-20

Applicant: KARYOPHARM THERAPEUTICS INC.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  Dilara McCauley ,  Trinayan Kashyap ,  William Senapedis ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Shechter

IPC: C07D401/06 ,  C07D249/08 ,  C07D413/06 ,  C07D405/06 ,  C07D417/06 ,  C07D403/06

CPC classification number: C07D401/06 ,  C07D249/08 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula (I) or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Abstract translation: 本发明涉及式（I）化合物及其药学上可接受的盐，包含式（I）化合物或其药学上可接受的盐的药物组合物，以及使用所述化合物，盐和组合物治疗各种疾病的方法 与CRM1活动相关。